Status:

COMPLETED

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy

Lead Sponsor:

AiViva BioPharma, Inc.

Conditions:

Keloid

Scar

Eligibility:

All Genders

18-60 years

Phase:

PHASE1

Brief Summary

To evaluate the saftye and effectiveness of AIV001 treatment on scar formation and/or keloid scar recurrence following keloidectomy.

Detailed Description

AIV001 (axitinib) has been formulated to provide focal disease-modifying therapy for patients undergoing surgical procedures where scar formation will occur. This was a multicenter, dose-escalation op...

Eligibility Criteria

Inclusion

  • Male of female, aged 18 to 60, inclusive
  • No clinically relevant abnormalities identified by a detailed medical history and vital signs
  • Presence of one keloid scar, up to 2.2 cm length and up to 1.2 cm width, at least 1 year from formation, and located on trunk or arms
  • Willing to undergo surgical excision of keloid
  • No concurrent treatment of the study keloid or prior treatment within last 2 months

Exclusion

  • Prior keloidectomy of study keloid
  • History of genetic disorder that predisposes to keloids (e.g., Ehlers-Danlos syndrome, Ullrich congenital muscular dystrophy, etc.)
  • Corticosteroids (topical, injectable, inhalable, intranasal, or oral) within last two months (except as prescribed by physician for seasonal allergies)
  • Clinically relevant cardiovascular, endocrine, hepatic, neurologic, renal, or other major systemic disease that could complicate execution of the protocol or interpretation of the study results
  • History of thrombotic events, hemorrhagic events, and gastrointestinal perforation and fistula
  • Subject has active collagen vascular disease or vasculitis, e.g., systemic lupus erythematosus, polyarthritis, dermatomyositis, systemic scleroderma or thrombotic thrombocytopenic purpura

Key Trial Info

Start Date :

June 23 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 15 2022

Estimated Enrollment :

25 Patients enrolled

Trial Details

Trial ID

NCT04827875

Start Date

June 23 2021

End Date

December 15 2022

Last Update

December 27 2024

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

California Dermatology & Clinical Research Institute

Encinitas, California, United States, 92024

2

Skin Research Institute

Coral Gables, Florida, United States, 33146

3

DermResearch DRI

Austin, Texas, United States, 78759

4

J&S Studies

College Station, Texas, United States, 77845

Safety and Efficacy of AIV001 on Scar Formation and Keloid Recurrence Following Keloidectomy | DecenTrialz